Jacob Wackerhausen/iStock via Getty Images Biohaven (NYSE:BHVN) Released an update for several of its programs from its pipeline for its R&D Day release. While this update noted advancements across several of its program, there is a catalyst opportunity that investors can look forward to with respect to a phase 3 program. This would be the use of its myostatin inhibitor taldefgrobep alfa [BHV-2000] for the treatment of patients with spinal muscular atrophy [SMA]. Data from this phase 3 trial, using this ...